Literature DB >> 20496313

Medical treatment of hyperthyroidism: state of the art.

A Fumarola1, A Di Fiore, M Dainelli, G Grani, A Calvanese.   

Abstract

Methimazole (MMI) and propylthiouracil (PTU) are the main antithyroid drugs used for hyperthyroidism. They inhibit the synthesis of thyroid hormone at various levels and are used as the primary treatment for hyperthyroidism or as a preparation before radioiodine therapy or thyroidectomy. MMI is the drug of choice because of its widespread availability, longer half-life and small number of severe side effects. Drugs of second choice are potassium perchlorate, beta blockers, iodine, lithium carbonate and glucocorticoids. Rituximab, a monoclonal antibody directed against human CD20, was recently proposed as a biological therapy for cases of Graves' disease unresponsive to traditional drugs. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20496313     DOI: 10.1055/s-0030-1253420

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  11 in total

1.  2-Seleno-1-alkylbenzimidazoles and their Diselenides: Synthesis and Structural Characterization of a 2-Seleno-1-methylbenzimidazole Complex of Mercury.

Authors:  Joshua H Palmer; Gerard Parkin
Journal:  Polyhedron       Date:  2012-08-07       Impact factor: 3.052

2.  Coordination of 1-methyl-1,3-dihydro-2H-benzimidazole-2-selone to zinc and cadmium: Monotonic and non-monotonic bond length variations for [H(sebenzimMe)]2MCl2 complexes (M = Zn, Cd, Hg).

Authors:  Patrick J Quinlivan; Mahnaz Rostami Chaijan; Joshua H Palmer; Daniel G Shlian; Gerard Parkin
Journal:  Polyhedron       Date:  2019-01-14       Impact factor: 3.052

3.  Synthesis and Structural Characterization of 1-Arylimidazole-2-thiones and N,N'-Aryldiethoxyethylthioureas with Electronically Diverse Substituents: A Manifold of Hydrogen Bonding Networks.

Authors:  Joshua H Palmer; Gerard Parkin
Journal:  New J Chem       Date:  2014-09-01       Impact factor: 3.591

Review 4.  Endocrine evaluation of erectile dysfunction.

Authors:  Andrea Sansone; Francesco Romanelli; Daniele Gianfrilli; Andrea Lenzi
Journal:  Endocrine       Date:  2014-04-06       Impact factor: 3.633

5.  Protolytic cleavage of Hg-C bonds induced by 1-methyl-1,3-dihydro-2H-benzimidazole-2-selone: synthesis and structural characterization of mercury complexes.

Authors:  Joshua H Palmer; Gerard Parkin
Journal:  J Am Chem Soc       Date:  2015-03-30       Impact factor: 15.419

6.  Innovative Strategies to Develop Chemical Categories Using a Combination of Structural and Toxicological Properties.

Authors:  Monika Batke; Martin Gütlein; Falko Partosch; Ursula Gundert-Remy; Christoph Helma; Stefan Kramer; Andreas Maunz; Madeleine Seeland; Annette Bitsch
Journal:  Front Pharmacol       Date:  2016-09-21       Impact factor: 5.810

7.  A patient-specific treatment model for Graves' hyperthyroidism.

Authors:  Balamurugan Pandiyan; Stephen J Merrill; Flavia Di Bari; Alessandro Antonelli; Salvatore Benvenga
Journal:  Theor Biol Med Model       Date:  2018-01-09       Impact factor: 2.432

8.  An extremely high dietary iodide supply forestalls severe hypothyroidism in Na+/I- symporter (NIS) knockout mice.

Authors:  Giuseppe Ferrandino; Rachel R Kaspari; Andrea Reyna-Neyra; Nabil E Boutagy; Albert J Sinusas; Nancy Carrasco
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

9.  MOK, a pharmacopuncture medicine, regulates thyroid dysfunction in L-thyroxin-induced hyperthyroidism in rats through the regulation of oxidation and the TRPV1 ion channel.

Authors:  Ji Hye Hwang; Seok Yong Kang; An Na Kang; Hyo Won Jung; Chul Jung; Jin-Ho Jeong; Yong-Ki Park
Journal:  BMC Complement Altern Med       Date:  2017-12-15       Impact factor: 3.659

10.  Assessment of tear-evaporation rate in thyroid-gland patients.

Authors:  Ali Abusharaha; Abdulaziz A Alturki; Saud A Alanazi; Raied Fagehi; Naji Al-Johani; Gamal A El-Hiti; Ali M Masmali
Journal:  Clin Ophthalmol       Date:  2019-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.